×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

Ñо¿ÓÃÓڷΰ©ºÍÐþÉ«ËØÁöϸ°û·Î×ªÒÆµÄÑ¡ÔñÐÔPAK4ÒÖÖÆ¼ÁµÄºÏ³É £¬´ËÑ¡ÔñÐÔPAK4ÒÖÖÆ¼ÁµÄPKÑо¿Í¨¹ý×ðÁú¿­Ê±¾ÙÐÐ

2023-06-28
|
»á¼ûÁ¿£º

1-Compound-55-is-effective-in-the-treatment-of-metastatic-cancer-1.jpg

The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic cancer. The pharmacokinetic study of Compound 55 was carried out by Medicilon.

Reference

Peilu Song, et al. Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells. Acta Pharm Sin B. 2022 Jun;12(6):2905-2922. doi: 10.1016/j.apsb.2022.02.029.

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿